ADVENTRX Pharmaceuticals announces 6-month balance data for Exelbine ADVENTRX Pharmaceuticals, Inc. The 6-month stability data are on the right track to support the submission of the New Drug Software for Exelbine. Culley, Chief Executive Officer of ADVENTRX eriactaranbaxy.org . After we have the 12-month data, we will post the Exelbine NDA, which we expect will take place in the fourth quarter of the full year. .
Scarcity of terminal ADP-ribose protein glycohydrolase TARG1/C6orf130 in neurodegenerative disease.. ADP-ribose plays key part in repairing cellular DNA damage Attaching chains of the tiny molecule ADP-ribose to proteins is very important to a cell's survival and the restoration of DNA damage, causeing this to be process a promising target for the development of new cancer medications. Researchers have finally identified a much sought after enzyme that removes such ADP-ribose modifications from proteins by learning a genetic mutation that triggers neurodegenerative disease in human beings. These findings, today in The EMBO Journal released, suggest that not only addition but also removal of ADP-ribose from proteins is essential for regular cell function.